clinical trial · NCT06911320
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Healthy Volunteer StudyHepatic ImpairmentRenal ImpairmentBemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
brief summary
To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose
started
Apr 9, 2025
primary completion
May 1, 2026
completion
May 1, 2026
last updated
Apr 13, 2026
official title
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of Bemnifosbuvir and Ruzasvir Administered as a Fixed-Dose Combination in Adult Participants With Severe Renal or Hepatic Impairment in Comparison to Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol